NCCN Congress Highlights

New York, NY—The FDA approvals of obinutuzumab (Gazyva), ofatumumab (Arzerra), ibrutinib (Imbruvica), and idelalisib (Zydelig) have changed the treatment paradigm of patients with chronic lymphocytic leukemia (CLL).
Read Article

New York, NY—In a debate on the role of rituximab (Rituxan) maintenance therapy in patients with follicular lymphoma at the 2014 National Comprehensive Cancer Network Congress, the protagonist and antagonist were not that far apart.
Read Article

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: